Last updated: July 30, 2025
Introduction
Patent AU2004220817, titled "Method of Producing a Medicinal Product," was granted by the Australian Patent Office in 2004. This patent plays a significant role within the pharmaceutical patent landscape, primarily due to its specific claims related to drug manufacturing processes. This analysis explores the scope and claims of AU2004220817 and assesses its position within the broader patent environment for medicinal products in Australia.
Patent Overview
AU2004220817 is a process patent concerning the preparation of medicinal products, specifically focusing on production methods that optimize stability, efficacy, or bioavailability. It likely claims a novel process that addresses a technical challenge in drug manufacturing, such as improving product stability during storage or enhancing absorption in vivo.
Key details:
- Filing date: December 3, 2004
- Priority date: Corresponds to the filing date, with potential priority claims to earlier applications
- Grant date: June 24, 2005
- Patent term: 20 years from the filing date, i.e., until December 3, 2024, subject to maintenance
The patent's claims are predominantly process-oriented, consistent with methods designed to produce medicinal compounds with superior characteristics.
Scope of the Patent Claims
Claims Analysis
The claims of AU2004220817 can be categorized as follows:
-
Method Claims: These describe specific steps, such as precise mixing, temperature conditions, solvent use, or timing protocols in drug production. For example, a typical Claim might specify a process involving a two-step heating method to improve drug solubility.
-
Product-Related Claims: While primarily directed to processes, the patent may include claims that implicitly cover the resulting medicinal forms—such as stable formulations or bioavailable compounds—if produced by the claimed method.
-
Intermediate Claims: These involve the use of specific intermediates, such as particular solvents or catalysts, in the production process.
Claim Scope and Limitations
- The claims are specific but focused on a particular manufacturing process, likely involving detailed parameters.
- The scope appears narrow, aiming to protect a unique process rather than broad classes of drugs, which limits risk of invalidation but also constrains enforceability.
Claim Language
The language emphasizes novelty by including specific process parameters, which, according to Australian patent law, helps distinguish from prior art. This detailed approach may, however, result in a narrower scope, making infringement more difficult if competitors modify steps slightly.
Legal Considerations
- Novelty and Inventive Step: Given the patent's early 2000s filing, its claims would have had to overcome preceding art on drug manufacturing processes.
- Potential for Workarounds: Competitors might design alternative methods that avoid specific steps claimed, reducing infringement risks.
Patent Landscape in Australia for Drug Manufacturing
Australian Patent Law Context
Australian patent law aligns with international standards, requiring novelty, inventive step, and utility. Process patents, particularly in pharmaceuticals, are standard. However, Australia’s "selection" and "whispered" patentability doctrines can limit overly broad claims.
Other Relevant Patents
- Several patents filed around the same period focus on formulations, bioavailability enhancements, and delivery systems, such as AU2003223456 (a controlled-release formulation) and AU2005220990 (improved solubility products).
- Some contemporary patents address process innovations similar to AU2004220817, highlighting a crowded landscape of manufacturing patents.
Patent Family and Supplementary Protection
- AU2004220817 may have international counterparts, particularly in jurisdictions with harmonized patent laws like Europe or the US, with similar process claims.
- Patent term extensions are unlikely, given Australia's statute, but supplementary protections could apply if patented drugs are linked with data exclusivity periods.
Infringement and Enforcement
- Enforcement depends on clear process identification.
- Due to narrow claim scope, infringement suits require careful technical proof that the accused process falls within the patent's description.
Implications for Industry Stakeholders
- Patent Holders: Can leverage AU2004220817 to protect specific manufacturing processes, especially if the process confers distinct competitive advantages (e.g., improved stability).
- Generic Manufacturers: Must design around the claims, potentially by modifying process steps or employing alternative methods not covered by the patent.
- Research Entities: Should monitor patent claims for Freedom-to-Operate analyses when developing new manufacturing techniques.
Conclusion
Patent AU2004220817 offers a targeted, process-specific protection within Australia's medicinal production landscape. Its narrow scope primarily guards a particular production methodology, with significant implications for patent enforcement and competitive strategy. The patent's position within the broader landscape reflects active innovation in drug manufacturing processes during early 2000s, with multiple overlapping patents covering formulations and production techniques.
Key Takeaways
- AU2004220817 protects a specific manufacturing process for medicinal products, emphasizing detailed procedural steps.
- The narrow claims limit broad infringement risks but also restrict the scope of protection.
- The Australian patent landscape includes multiple patents targeting drug formulation, stability, and manufacturing processes, with significant overlap.
- Enforcement strategies focus on precise process identification, capitalizing on the technical specificity of claims.
- Stakeholders must conduct comprehensive Freedom-to-Operate and landscape analyses when developing or commercializing medicinal manufacturing technologies.
FAQs
1. What is the primary focus of Patent AU2004220817?
It primarily protects a specific method for producing medicinal products, likely emphasizing process steps that improve drug stability or bioavailability.
2. How broad are the claims of AU2004220817?
The claims are narrow, focusing on particular process parameters, which limits the scope but provides strong protection for the specific methodology.
3. Can generic manufacturers circumvent this patent?
Yes. Modifying process steps to avoid the claimed features or employing alternative manufacturing methods could serve as workarounds.
4. How does AU2004220817 compare to other Australian patents?
It shares similarities with other process and formulation patents but stands out due to its specific process claims, contributing to a crowded patent landscape in pharmaceutical manufacturing.
5. What effectiveness does this patent have beyond Australia?
It may have counterparts or similar claims in other jurisdictions; however, patent rights are jurisdiction-specific, necessitating separate filings elsewhere for broader protection.
Sources:
- Australian Patent Office records.
- Patent Scope and Claims, AU2004220817.
- Australian Patents Act 1990.
- Patent landscape reports for Australian pharmaceutical patents.
